Canaccord Genuity Sees GenMark Diagnostics (GNMK) Trading Above Buyout Comps, PT Raised to $24
Tweet Send to a Friend
Canaccord Genuity analyst Max Masucci raised the price target on GenMark Diagnostics (NASDAQ: GNMK) to $24.00 (from $22.00) using history ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
